Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

Background: The three interferon beta preparations approved for treatment of relapsing-remitting multiple sclerosis (MS) differ in dose and frequency of administration. Interferon beta-1a 30 microg is administered once a week, interferon beta-1a 22 microg or 44 microg is given three times a week, an...

Descripción completa

Detalles Bibliográficos

Publicado en:	Lancet Vol. 359; no. 9316; pp. 1453 - 1461
Autores principales:	Durelli, Luca, Verdun, Elisabetta, Barbero, Pierangelo, Bergui, Mauro, Versino, Elisabetta, Ghezzi, Angelo, Montanari, Enrico, Zaffaroni, Mauro
Formato:	clinical trial research randomized controlled trial Journal Article
Publicado:	Lancet 4/27/2002
Acceso en línea:	Ver este registro en EBSCOhost